Pharmaceutical Benefits Scheme

We work to secure timely and equitable access to respiratory medicines that improve the health, social and economic outcomes of people impacted by lung disease or lung cancer.

To do this, we make submissions to the Pharmaceutical Benefits Advisory Committee (PBAC) – the body that decides which medicines should be subsidised by the Federal Government under Pharmaceutical Benefits Scheme (PBS). We also support our members to make individual submissions to the PBAC.

You can find information on the PBAC here and the PBS here.

We seek the views and experiences of our members, of treatments under consideration by the PBAC, in advance of PBAC meetings. For more information on the meeting schedule of the PBAC, outcomes and public summary documents please click here.

If you wish to make an individual submission to the PBAC regarding a proposed listing, we recommend accessing the guides featured below and the Patient Voice Initiative website for support in preparing a submission.

PBAC March 2021 Outcomes and July Agenda Items

At the March meeting the Pharmaceutical Benefits Advisory Committee made two positive recommendations to list or change the listing of respiratory therapies on the Pharmaceutical Benefits Scheme (PBS).

Lung Foundation Australia is seeking input from consumers to inform our submissions to the PBAC on the proposed listings of Breztri Aerosphere®, a triple therapy (budesonide, formoterol fumarate dihydrate and glycopyrronium) for people with moderate to severe Chronic Obstructive Pulmonary Disease. Click here to complete a short survey to have your say.

To view the outcomes of the March meeting and July agenda items, follow the link below.